Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer

Cancer Science

Volumn 104, Issue 12, 2013, Pages 1683-1689

  Chen, Yi Fei ^a   Dong, Zhangli ^a   Xia, Yi ^b,c   Tang, Jingjie ^b   Peng, Ling ^b   Wang, Shuying ^a   Lai, Dongmei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; LY 101 4B; MESSENGER RNA; MICRORNA 214; NUCLEOSIDE ANALOG; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOMA; DISEASE ASSOCIATION; DOWN REGULATION; DRUG TARGETING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SCORING SYSTEM; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEOSIDES; OVARIAN NEOPLASMS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84889569982     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12277     Document Type: Article

References (27)

1. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett 2013; 338: 147-57.
2. Cho KR. Shih IeM. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
3. Sudo T. Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol 2012; 17: 424-9.
4. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130: 1005-18.
5. de Billy E, Powers MV, Smith JR, Workman P. Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell Cycle 2009; 8: 3806-8.
6. Whitesell L, Lindquist S. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets 2009; 13: 469-78.
7. Mendillo ML, Santagata S, Koeva M et al. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012; 150: 549-62.
8. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi NF. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 2007; 26: 5086-97.
9. Logan IR, McNeill HV, Cook S et al. Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage. Nucleic Acids Res 2009; 37: 2962-73.
10. Meng L, Gabai VL, Sherman MY. Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene 2010; 29: 5204-13.
11. Santagata S, Hu R, Lin NU et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci USA 2011; 108: 18378-83.
12. Jin X, Moskophidis D, Mivechi NF. Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab 2011; 14: 91-103.
13. Fang F, Chang R, Yang L. Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer 2012; 118: 1782-94.
14. Xia Y, Liu Y, Rocchi P et al. Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer. Cancer Lett 2012; 318: 145-53.
15. Xia Y, Qu F, Peng L. Triazole nucleoside derivatives bearing aryl functionalities on the nucleobases show antiviral and anticancer activity. Mini Rev Med Chem 2010; 10: 806-21.
16. Xia Y, Liu Y, Wan J et al. Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem 2009; 52: 6083-96.
17. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets 2012; 16: 747-59.
18. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013; 18: 282-9.
19. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-64.
20. Nam EJ, Yoon H, Kim SW et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14: 2690-5.
21. Dahiya N, Morin PJ. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 2010; 17: F77-89.
22. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 2010; 42: 1262-72.
23. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.
24. Chen YF, Dong Z, Jiang L, Lai D, Guo L. Mouse primed embryonic stem cells could be maintained and reprogrammed on human amnion epithelial cells. Stem Cells Dev 2013; 22: 320-9.
25. Zhang J, Du YY, Lin YF et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun 2008; 377: 136-40.
26. Creighton CJ, Fountain MD, Yu Z et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 2010; 70: 1906-15.
27. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.